6-K

FORM 6-K

U.S. SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

REPORT OF FOREIGN PRIVATE ISSUER

PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE

SECURITIES EXCHANGE ACT OF 1934

dated October 27, 2020

Commission File Number 0-51504

GENETIC TECHNOLOGIES LIMITED

(Exact Name as Specified in its Charter)

N/A

(Translation of Registrant’s Name)

60-66 Hanover Street

Fitzroy

Victoria 3065 Australia

(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F [X] Form 40-F [  ]

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): [  ]

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): [  ]

Indicate by check mark whether by furnishing the information contained in this Form, the registrant is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.

Yes [  ] No [X]

If “Yes” is marked, indicate below the file number assigned to the registrant in connection with Rule 12g3-2(b): Not applicable.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused the Report to be signed on its behalf by the undersigned, thereunto duly authorized.

Date: October 27, 2020

GENETIC TECHNOLOGIES LIMITED
By:	/s/ Justyn Stedwell
Name:	Justyn Stedwell
Title:	Company Secretary

2

EXHIBIT INDEX

Exhibit	Description of Exhibit
99.1	Genetic Technologies Quarterly Investor Webinar

3

EX-99.1

Exhibit 99.1

Genetic Technologies Quarterly Investor Webinar

Melbourne, Australia, 27 October 2020: Molecular diagnostics company Genetic Technologies Ltd (ASX: GTG; NASDAQ: GENE, “Company”), will provide an investor webinar to discuss the quarterly results and further advancements to its diagnostic tests for the period ending 30 September 2020 to be released to the market on Friday 30 October 2020.

The Company will host the webinar via Zoom and it is expected to last approximately 45 minutes.

To register please follow the link below.

Date: Friday 30^th October 2020

Time: 11:30am AEDT

Registration Link: https://us02web.zoom.us/webinar/register/WN_mkXCxcAlSJizX3DP0gYuug

The announcement was approved by the Board of Directors.

Investor Relations (AUS)	Investor Relations and Media (US)
Stephanie Ottens	Mr Dave Gentry RedChip Office:
Market Eye	1 800 RED CHIP (733 2447)
M: +61 434 405 400	Cell: 407 491 4498
E: stephanie.ottens@marketeye.com.au	E: dave@redchip.com

About Genetic Technologies Limited Genetic Technologies Limited (ASX: GTG; Nasdaq: GENE) is a diversified molecular diagnostics company. GTG offers cancer predictive testing and assessment tools to help physicians proactively manage patient health. The Company’s lead products GeneType for Breast Cancer for non-hereditary breast cancer and GeneType for Colorectal Cancer are clinically validated risk assessment tests and are first in class. Genetic Technologies is developing a pipeline of risk assessment products.

For more information, please visit www.gtglabs.com